Jaguar Health Announces Approval of All Proposals at Annual Meeting

Jaguar Health, Inc. reported successful approval of all seven proposals at their Annual Meeting of Stockholders on August 19, 2025. The company highlighted positive results from a trial in Abu Dhabi, where crofelemer showed significant reductions in parenteral nutrition needs for microvillus inclusion disease and short bowel syndrome patients.

The FDA meeting paved the way for Jaguar's supplemental NDA strategy for crofelemer for metastatic breast cancer patients, recognized as an orphan population in the US. Jaguar aims to develop partnerships for the commercialization of its orphan indication products to secure non-dilutive funding.

CEO Lisa Conte will present updates on near-term catalysts at the Emerging Growth Conference on August 20. The company remains focused on advancing crofelemer and expanding its applications across various health conditions.